Orthomol, the premium multivitamin brand distributed by Donga Pharmaceutical, has ranked No. 1 in sales in the Korean market for three consecutive years.
Donga Pharmaceutical said on the 31st that Orthomol maintained the top position by sales value in Korea's online and offline multivitamin market from 2023 through 2025, according to a survey by global research firm Euromonitor International. The survey covered all distribution channels, including over-the-counter pharmaceuticals.
Orthomol is a premium multivitamin brand for which Donga Pharmaceutical serves as the official distribution partner in Korea. The company entered the domestic market in 2020 with the launch of its flagship product, Immun. In 2023, it expanded its product lineup with Vital M and Vital F, all-in-one formulas tailored to individual health needs.
Immun is formulated with vitamins B, C, and E, as well as niacin and zinc, to help support immune function. The Vital line contains up to 23 types of nutrients, including omega-3, to support everyday health management.
Expansion of distribution channels also contributed to the results. Donga Pharmaceutical broadened its sales reach beyond offline channels such as health-and-beauty stores and department stores to include mobile commerce and online shopping platforms, improving accessibility. The omnichannel distribution strategy is credited with strengthening consumer touchpoints.
Orthomol differentiated itself by positioning its products not just as function-focused supplements but as premium health gifts. Its dual-format design, combining liquid and tablet forms, emphasizes both convenience and user experience, establishing a unique market position.
The multivitamin market has recently seen growing demand for balanced nutritional formulas and product configurations tailored to individual lifestyles. Orthomol has maintained its market standing amid this trend on the strength of brand credibility and product competitiveness.
"The products distributed in Korea maintain the research standards of the German headquarters while reflecting the nutritional intake characteristics of Korean consumers," a Donga Pharmaceutical official said. "We plan to continuously strengthen our growth foundation by expanding our range of formulations and product lines."
